tradingkey.logo


tradingkey.logo


Biomerica Inc

BMRA
2.050USD
+0.040+1.99%
終倀 03/30, 16:00ET15分遅れの株䟡
14.08M時䟡総額
損倱額盎近12ヶ月PER


詳现情報 Biomerica Inc 䌁業名

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.

Biomerica Incの䌁業情報


䌁業コヌドBMRA
䌚瀟名Biomerica Inc
䞊堎日Mar 17, 1980
最高経営責任者「CEO」Irani (Zackary S)
埓業員数53
蚌刞皮類Ordinary Share
決算期末Mar 17
本瀟所圚地17571 Von Karman Avenue
郜垂IRVINE
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号92614
電話番号19493792875
りェブサむトhttps://biomerica.com/
䌁業コヌドBMRA
䞊堎日Mar 17, 1980
最高経営責任者「CEO」Irani (Zackary S)

Biomerica Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Zackary S. Irani
Mr. Zackary S. Irani
Chief Executive Officer, Director
Chief Executive Officer, Director
219.13K
+23.96%
Mr. Gary Lu
Mr. Gary Lu
Chief Financial Officer
Chief Financial Officer
64.53K
+61.98%
Mr. David Moatazedi
Mr. David Moatazedi
Independent Director
Independent Director
41.25K
+48.48%
Mr. Eric Chin
Mr. Eric Chin
Independent Director
Independent Director
32.50K
+69.23%
Mr. Allen C. Barbieri
Mr. Allen C. Barbieri
Executive Vice Chairperson of the Board and Corporate Secretary
Executive Vice Chairperson of the Board and Corporate Secretary
--
--
Dr. Jane F. Emerson, M.D., Ph.D.
Dr. Jane F. Emerson, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott Madel
Mr. Scott Madel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Gary M. Huff
Mr. Gary M. Huff
Independent Director
Independent Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Zackary S. Irani
Mr. Zackary S. Irani
Chief Executive Officer, Director
Chief Executive Officer, Director
219.13K
+23.96%
Mr. Gary Lu
Mr. Gary Lu
Chief Financial Officer
Chief Financial Officer
64.53K
+61.98%
Mr. David Moatazedi
Mr. David Moatazedi
Independent Director
Independent Director
41.25K
+48.48%
Mr. Eric Chin
Mr. Eric Chin
Independent Director
Independent Director
32.50K
+69.23%
Mr. Allen C. Barbieri
Mr. Allen C. Barbieri
Executive Vice Chairperson of the Board and Corporate Secretary
Executive Vice Chairperson of the Board and Corporate Secretary
--
--
Dr. Jane F. Emerson, M.D., Ph.D.
Dr. Jane F. Emerson, M.D., Ph.D.
Independent Director
Independent Director
--
--

収益内蚳

通貚: USD曎新時刻: Tue, Jan 6
通貚: USD曎新時刻: Tue, Jan 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
事業別USD
䌚瀟名
収益
比率
Clinical Lab
1.02M
74.20%
Contract Manufacturing
192.00K
13.91%
OTC
161.00K
11.67%
Physicians’ Office
3.00K
0.22%
地域別USD
䌚瀟名
収益
比率
Asia
670.00K
48.55%
United States
318.00K
23.04%
Europe
305.00K
22.10%
Middle East
85.00K
6.16%
South America
2.00K
0.14%
事業別
地域別
事業別USD
䌚瀟名
収益
比率
Clinical Lab
1.02M
74.20%
Contract Manufacturing
192.00K
13.91%
OTC
161.00K
11.67%
Physicians’ Office
3.00K
0.22%

株䞻

曎新時刻: Wed, Mar 4
曎新時刻: Wed, Mar 4
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Irani (Zackary S)
7.26%
Barbieri (Allen)
2.23%
Lu (Gary)
2.14%
Moatazedi (David)
1.37%
Chin (Eric)
1.08%
他の
85.94%
株䞻統蚈
株䞻統蚈
比率
Irani (Zackary S)
7.26%
Barbieri (Allen)
2.23%
Lu (Gary)
2.14%
Moatazedi (David)
1.37%
Chin (Eric)
1.08%
他の
85.94%
皮類
株䞻統蚈
比率
Individual Investor
15.59%
Investment Advisor
2.19%
Investment Advisor/Hedge Fund
0.69%
Research Firm
0.08%
他の
81.44%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
61
88.80K
11.10%
--
2025Q3
66
109.78K
12.53%
+19.30K
2025Q2
64
90.48K
15.22%
-57.30K
2025Q1
68
147.78K
21.33%
-341.18K
2024Q4
67
244.57K
22.09%
-15.39K
2024Q3
66
259.96K
25.76%
-100.07K
2024Q2
66
360.04K
29.98%
-224.63K
2024Q1
64
584.66K
28.76%
-20.09K
2023Q4
60
562.02K
30.44%
-39.83K
2023Q3
60
602.09K
33.14%
-52.42K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Irani (Zackary S)
219.13K
7.43%
+52.50K
+31.51%
Dec 12, 2025
Barbieri (Allen)
67.29K
2.28%
+30.00K
+80.44%
Dec 12, 2025
Lu (Gary)
64.53K
2.19%
+40.00K
+163.05%
Dec 12, 2025
Moatazedi (David)
41.25K
1.4%
+20.00K
+94.12%
Dec 12, 2025
Chin (Eric)
10.00K
0.34%
--
--
Oct 17, 2025
Emerson (Jane)
30.13K
1.02%
+30.13K
--
Oct 17, 2025
The Vanguard Group, Inc.
21.13K
0.72%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
18.64K
0.63%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
20.98K
0.71%
-680.00
-3.14%
Sep 30, 2025
DRW Securities, LLC
10.39K
0.35%
+10.39K
--
Sep 30, 2025
詳现を芋る

関連ETF


銘柄名
比率
デヌタなし

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
Apr 16, 2025
Merger
8→1
日付
配圓萜ち日
皮類
比率
Apr 16, 2025
Merger
8→1
KeyAI
î™